This study investigates the efficacy and safety of an investigational medication in people with moderately to severely active Crohn's Disease. Participants will be part of a study lasting up to 35 weeks. This includes a screening period of up to 5 weeks, followed by a treatment duration of up to …
This study investigates the long-term safety and efficacy of an investigational medication in adults with asthma. It is an extension of previous studies and will last up to 100 weeks, with participants receiving treatment for up to 96 weeks. The purpose of this study is to continue monitoring the effects …
This study investigates the effect of an investigational medication on airway inflammation in people with Chronic Obstructive Pulmonary Disease (COPD). Participants will be in the study for up to 40 weeks. During this time, the effects on airway resistance and remodeling, including mucus plugging, will be assessed to see if …
This study investigates the safety and effectiveness of an investigational medication for people aged 12 and older with moderate to severe atopic dermatitis. Participants will be involved in the study for up to 284 weeks. This includes a screening period lasting 2 to 4 weeks, a treatment period of up …
This study investigates the treatment of Systemic Lupus Erythematosus (SLE) using an investigational medication compared to a placebo. Participants will be involved in the study for a total of 36 weeks, with the treatment phase lasting 24 weeks. This means that individuals will participate in the study for over half …
This study investigates the efficacy and safety of an investigational medication for subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD). The study involves participants who have not responded adequately to previous biologic or oral JAK inhibitor therapies, and who are currently using topical corticosteroids …
The purpose of this study is to investigate the effects of investigational medications on primary focal segmental glomerulosclerosis (FSGS) and primary minimal change disease (MCD) in participants aged 16 to 75 years. The study will last up to 76 weeks, and participants will be involved for this entire duration. FSGS …
This study investigates the efficacy and safety of an investigational medication given as a preventative treatment to young male participants aged 1 to less than 12 years with severe hemophilia A or B. The study is open-label and involves two study arms: participants who have not been previously treated with …
This study investigates the effects of an investigational medication in adults with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The purpose is to see if the medication can delay disability progression compared to a placebo. Participants will be in the study for up to 43 months, starting from when the first …
This study investigates the effectiveness and safety of an investigational medication for adults with chronic pruritus of unknown origin (CPUO). The study includes two parallel-treatment, double-blind, Phase 3 trials (Study A and Study B) designed to compare the investigational medication with a placebo in participants aged 18 to 90 years.Participants …
